Observational studyBMC medicine2025
Mid-term outcomes of paclitaxel-coated balloon for de novo non-small coronary lesions: a pooled analysis.
Observational study in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Polymer-free Sirolimus-eluting Coronary Stents in Patients With Coronary Artery Disease.
HELIOS China Registry: A Prospective, Single-arm, Multicenter Study to Evaluate the HELIOS Biodegradable Polymer Sirolimus-eluting Stent in a 'Real-World' Patient Population
The Clinical Efficacy and Safety of Drug-coated Balloon in Coronary Lesions: a Real-World, All-Comers ,Single-center, Prospective Study
Who cites it
1 citing paper in PubMed.
- Prognostic Value of Computational Pressure-Flow Dynamics Derived FFR Measured Immediately After Successful Paclitaxel‑Coated Balloon Angioplasty for In-Stent Restenosis Lesion.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe efficacy of drug-coated balloons (DCB) for the treatment of de novo, non-small coronary lesions remains uncertain. This study aimed to evaluate the real-world performance of DCB-only angioplasty in this setting.
methodsPatients with de novo, non-small coronary lesions (≥ 2.5 mm) treated exclusively with either drug-eluting stents (DES) or DCB were included from the DCB registry and two DES registries. The primary endpoint was the device-oriented composite endpoint (DoCE), including cardiovascular death, non-fatal target vessel myocardial infarction (TV-MI), and target lesion revascularization (TLR). Differences between cohorts were compared and adjusted by inverse probability of treatment weighting (IPTW).
resultsThe study included 4621 patients, with 3780 in the DES group and 841 in the DCB group. At 3 years, the primary endpoint occurred in 51 (6.1%) patients receiving DCB and 143 (3.8%) patients with DES (HR
conclusionsDCB-only angioplasty is associated with a higher rate of DoCE and TLR compared with DES group in patients with de novo coronary lesions which were ≥ 2.5 mm in diameter.
trial registrationRegistered on clinicaltrials.gov (NCT02929030, NCT03916432, and NCT05133921).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.